Instil Bio Non-GAAP EPS of -$3.24

* Instil Bio press release [https://seekingalpha.com/pr/20198987-instil-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:TIL [https://seekingalpha.com/symbol/TIL]): Q2 Non-GAAP EPS of -$3.24.
* As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash,
*

MORE ON INSTIL BIO

* Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups [https://seekingalpha.com/article/4798441-instil-bio-chasing-after-summit-and-biontech-albeit-with-some-hiccups]
* Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates [https://seekingalpha.com/article/4789766-investing-in-the-promising-pd1vegf-bispecific-pfizer-and-instil-could-be-good-candidates]
* Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success [https://seekingalpha.com/article/4789697-instil-bio-axn-2510-data-could-mark-another-pd-1vegf-success]
* Instil Bio to begin testing antibody therapy in solid tumors [https://seekingalpha.com/news/4464861-instil-bio-to-begin-testing-antibody-therapy-in-solid-tumors]
* Instil Bio appoints Jamie Freedman as Chief Medical Officer [https://seekingalpha.com/news/4454184-instil-bio-appoints-jamie-freedman-as-chief-medical-officer]